

AUG 2 5 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Signus Medical, LLC. c/o Ms.Tracy Gray Principal Consultant Alquest, Inc. 4050 Olson Memorial Highway, Suite 350 Minneapolis, Minnesota 55422

Re: K052096

Trade/Device Name: NUBIC[™] Spinal Implant

Regulation Number: 21 CFR 888.3060

Regulation Name: Spinal intervertebral body fixation orthosis

Regulatory Class: II Product Code: MQP Dated: July 29, 2005

Received: August 4, 2005

Dear Ms. Gray:

This letter corrects our substantially equivalent letter of August 16, 2005. The Company title has been changed to reflect the correct owner of the 510(k), Signus Medical, LLC., as indicated in your 510(k) submission.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Acting Director

Division of General, Restorative, and Neurological Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications	for	Use	Page

510(k) Number (if known): <u>KOS</u>2046

Device Name:

NUBIC™ Spinal Implant

Indications for Use:

The NUBIC™ Spinal Implant is indicated for use to replace a vertebral body that has been resected or excised due to tumor or trauma/fracture. The device is intended for use as a vertebral body replacement in the thoracolumbar spine (from T1 to L5) and is intended for use with supplemental internal fixation.

The NUBIC™ may be implanted singularly or in pairs.

The supplemental internal fixation systems that may be used with the NUBIC™ Spinal Implant include, but are not limited to, SIGNUS CONKLUSION System, DcPuy AcroMed titanium plate or rod systems (Kaneda SR, University Plate, M2, ISOLA, VSP, Moss, TiMX, and Profile).

Prescription Use X (Per 21 CFR 801 Subpart D) AND/OR

Over-the-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

Appendix B Page 2

AUG 1 6 2005

510(k) Summary

Submitter:	SIGNUS Medizintechnik GMBH		
Submitter.	Brentanostr. 9		
	Alzennau, Germany D-63755		
	49-6023 9166-0		
Contact Person:	Tracy L. Gray, RN, BS RAC		
Contact x 0150m	Principal Consultant		
	Alquest, Inc.		
	Phone: (763) 588-9873 Fax: (763) 287-3836		
Date Prepared:	July 29, 2005		
Trade Name:	NUBIC™ Spinal Implant		
Classification	21 CFR 888.3060		
Name and			
Number:			
Product Code:	MQP		
Predicate Device	RABEA™ cleared under K043316.		
Device Description:	The NUBIC™ Spinal implant is a rectangular frame. The upper and		
-	lower aspects of the implant are open and the walls feature spikes which		
	assist in the positive anchorage and seating of the implant between the		
	superior and inferior vertebral bodies.		
	TI C ' C - I C - DEEK (DEEK OPTIMATM LT1) which is		
	The frame is forged from PEEK (PEEK-OPTIMA™ LT1), which is radiolucent, and incorporates small Titanium alloy (TiAl6V4) marker		
	pins so the device can be located within the body. The marker pins		
	meet ASTM F-136 and ISO 5832/3.		
	meet ASTWI F-130 and 15O 3632/3.		
	The NUBIC TM Spinal Implant is available in a variety of sizes ranging		
	from 4mm to 30mm. This enables the surgeon to choose the size suited		
	to the individual pathology and anatomical condition. The NUBIC TM		
	may be implanted individually or in pairs.		
Intended Use:	The NUBIC TM Spinal Implant is indicated for use to replace a vertebral		
intended Osc.	body that has been resected or excised due to tumor or trauma/fracture.		
	The device is intended for use as a vertebral body replacement in the		
	thoracolumbar spine (from T1 to L5) and is intended for use with		
	supplemental internal fixation.		
	Swpp		
	The NUBIC™ may be implanted singularly or in pairs.		
	The supplemental internal fixation systems that may be used with the		
	NUBIC™ Spinal Implant and include, but are not limited to, SIGNUS		
	CONKLUSION System, DePuy AcroMed titanium plate or rod systems		
	(Kaneda SR, University Plate, M2, ISOLA, VSP, Moss, TiMX, and		
	Profile).		
Statement of	The subject device and predicate device have the following similarities:		
Technological	The same indication for use;		
Comparison	The same operating principle;		
	The same basic design;		
	The same materials;		

	 Implanted using the same surgical techniques and equipment; Used in conjunction with the same types of supplemental internal fixation systems; The same manufacturing environment; The same sterilization process; and The same packaging configurations.
	In summary, the NUBIC TM , as described in this submission is, in the opinion of Signus Medical, LLC., substantially equivalent to the predicate device.
Conclusion:	The NUBIC TM as modified in this submission, is substantially equivalent to the predicate device, RABEA TM cleared under K043316. This conclusion is based upon the similarities of the devices in terms of functional design, indication for use, principles of operation, materials, and performance characteristics.